Arcutis shares down after earnings report
Westlake Village-based Arcutis Biotherapeutics suffered a net loss in the first quarter of fiscal year 2021, but continues to hold a strong financial position with $446.5 million in assets. According to earnings released May 4, Arcutis lost $36 million in the first quarter, or 76 cents per share, compared to a loss of $28 million, Read More →
Read More →Arcutis shares flat on earnings report
Arcutis Biotherapeutics saw a steep rise in operating expenses resulting in a 183% increase in net loss compared to the previous year when the company revealed its fourth quarter and full-year financial results on Feb. 16. However, the Westlake Village biotech company is still in high spirits, as the company is in a “strong financial Read More →
Read More →Arcutis stock soars on drug trial news; company announces $150M capital raise
Stock of Arcutis Biotherapeutics, a Westlake Village-based company developing dermatological treatments, shot up more than 30% on Feb. 1 after the company released positive results from a recent clinical trial. Later in the day, Arcutis said it plans to sell $150 million worth of its common stock. Before stock trading opened, the company announced positive Read More →
Read More →Arcutis shares up on news of public, private offerings
Arcutis Biotherapeutics saw a 15 percent rise in its share price after it said Sept. 29 that it will offer 4 million shares to the public and sell another $35 million in stock to an affiliate of one of its directors. Arcutis closed at $31.04, a gain of $4.28 after it announced the dual track Read More →
Read More →
Two Central Coast technology companies raise $150 million
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
